* Sun Pharmaceutical Industries Ltd up 1 percent aftera competitor raised its revenue guidance, citing strong sale ofa generic antibiotic also sold by Sun Pharma.* Hikma Pharmaceuticals Plc on Wednesday raised itsfull-year revenue forecast for the third time in four months,riding on strong sales of generic antibiotic doxycycline, a drugused to prevent and treat malaria and other infections. * Analysts expect generic doxycycline to contribute aroundUS$60-80 million in sales in FY14 for Sun Pharma. (abhishek.vishnoi@thomsonreuters.com /;abhishek.vishnoi.thomsonreuters.com@reuters.net)
Barclays downgrades Hikma to 'equalweight' on Generics concerns
(Sharecast News) - Barclays downgraded Hikma Pharmaceuticals on Friday to 'equalweight' from 'overweight' and cut the price target to 1,750p from 2,250p as it said a lack of visibility in the generics division was a real concern.
Read more